Akcie v oběhu společnosti SinoMab BioScience
Jaká je hodnota metriky Akcie v oběhu společnosti SinoMab BioScience?
Hodnota metriky Akcie v oběhu společnosti SinoMab BioScience Limited je 259.218M 25.76%
Jaká je definice metriky Akcie v oběhu?
Akce v oběhu (Shares float) je podíl akcií společnosti vlastněných veřejnými investory vůči zablokovaným akcím (nejsou volně v oběhu).
Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded
The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.
Akcie v oběhu společností v sektoru Health Care sektor na HKSE ve srovnání se společností SinoMab BioScience
Čemu se věnuje společnost SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Firmy s metrikou akcie v oběhu podobnou společnosti SinoMab BioScience
- Hodnota metriky Akcie v oběhu společnosti NXP Semiconductors N.V je 258.694M 87.54%
- Hodnota metriky Akcie v oběhu společnosti Bortex Global je 258.720M 51.74%
- Hodnota metriky Akcie v oběhu společnosti Wing Chi je 258.751M 27.71%
- Hodnota metriky Akcie v oběhu společnosti Luzheng Futures je 258.811M 93.40%
- Hodnota metriky Akcie v oběhu společnosti Kinnevik AB je 258.831M 107.08%
- Hodnota metriky Akcie v oběhu společnosti The Lakshmi Vilas Bank je 258.892M 76.89%
- Hodnota metriky Akcie v oběhu společnosti SinoMab BioScience je 259.218M 25.76%
- Hodnota metriky Akcie v oběhu společnosti Klondike Silver je 259.330M 98.92%
- Hodnota metriky Akcie v oběhu společnosti Lucero je 259.334M 39.15%
- Hodnota metriky Akcie v oběhu společnosti Canadian Overseas Petroleum je 259.371M 157.89%
- Hodnota metriky Akcie v oběhu společnosti Lapco je 259.400M 64.85%
- Hodnota metriky Akcie v oběhu společnosti Organto Foods je 259.421M 93.52%
- Hodnota metriky Akcie v oběhu společnosti JiaChen je 259.440M 25.94%